Core Viewpoint - Neuroblastoma is the most common extracranial solid tumor in children, characterized by significant developmental plasticity and intratumoral heterogeneity, leading to a 5-year survival rate of less than 50% in high-risk cases [2][8]. Group 1: Research Background - The study published by Professor Wang Jian's team from Suzhou University and Professor Hu Yizhou's team from Karolinska Institute in the journal Developmental Cell explores the developmental plasticity of neuroblastoma through single-cell multi-omics and spatial transcriptomics [2]. - Neuroblastoma originates from neural crest progenitor cells, which can differentiate into various cell types, including sympathetic neurons and chromaffin cells, and is influenced by genetic abnormalities and the tumor microenvironment [8][9]. Group 2: Research Findings - The research identified an intermediate "bridge" cell state crucial for malignant transformation in high-risk neuroblastoma, characterized by extensive epigenetic pre-activation features and potential for multidirectional state transitions [9][10]. - A transcription factor-enhancer gene regulatory network (TF-eGRN) was defined, which characterizes tumor states and is influenced by the specific microenvironment of the bridge/progenitor cell state, promoting mesenchymal characteristics [10].

4月1日，碧迪拟出售生命科学业务事件有了最新进展，该公司正与科学仪器行业两大巨头 赛默飞、丹纳赫 就出售其生命科学业务进行谈判。 此外，该公司还在与 沃特世、凯杰、瑞孚迪 等体量较小的潜在买家探索通过"反向莫里斯信托"免税换股方式完成交易。 早在2月6日，碧迪向外界披露了其正有条不紊地筹备拆分旗下极具价值的生命科学部门。该部门包括集成诊断解决方案（IDS）部门和生物科 学业务（BDB）部门。其中，IDS业务将保留在新的碧迪集团内。 导读： 4月1日，碧迪拟出售生命科学业务事件有了最新进展，该公司正与科学仪器行业两大巨头赛默飞、丹纳赫、沃特世、凯杰、瑞孚迪等就出售其生命科学业 务进行谈判。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 谁将成为最后赢家？ 如今，赛默飞、丹纳赫、沃特世、凯杰、瑞孚迪5潜在买家率先浮出水面，不意外的，都是科学仪器行业"知名老演员"。那么，谁将成为最后赢 家？ 据悉，此次拆分是由激进投资者St a r b o a r d Va l u e推动的。他们坚信，拆分后的生命科学部门能够摆脱原有的组织架构束缚，以更加独立 ...